Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Baxter
Chinese Patent Office
Merck
McKinsey
US Army
Cipla
US Department of Justice
AstraZeneca
Moodys

Generated: January 20, 2018

DrugPatentWatch Database Preview

COMPAZINE Drug Profile

« Back to Dashboard

When do Compazine patents expire, and when can generic versions of Compazine launch?

Compazine is a drug marketed by Glaxosmithkline and is included in seven NDAs.

The generic ingredient in COMPAZINE is prochlorperazine. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the prochlorperazine profile page.
Drug patent expirations by year for COMPAZINE
Medical Subject Heading (MeSH) Categories for COMPAZINE

US Patents and Regulatory Information for COMPAZINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline COMPAZINE prochlorperazine maleate CAPSULE, EXTENDED RELEASE;ORAL 011000-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine edisylate CONCENTRATE;ORAL 011276-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine maleate CAPSULE, EXTENDED RELEASE;ORAL 021019-002 Oct 6, 1999 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine edisylate SYRUP;ORAL 011188-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine edisylate INJECTABLE;INJECTION 010742-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine maleate TABLET;ORAL 010571-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine maleate CAPSULE, EXTENDED RELEASE;ORAL 021019-001 Oct 6, 1999 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine maleate CAPSULE, EXTENDED RELEASE;ORAL 011000-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine maleate CAPSULE, EXTENDED RELEASE;ORAL 011000-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline COMPAZINE prochlorperazine maleate CAPSULE, EXTENDED RELEASE;ORAL 011000-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Daiichi Sankyo
Queensland Health
QuintilesIMS
Accenture
Fuji
Mallinckrodt
Chinese Patent Office
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot